Research graph
References from Analysis of genes characterizing chronic thrombosis and associated pathways in chronic thromboembolic pulmonary hypertension. Local targets link to admitted publications; unresolved targets remain external evidence.
CTEPH: A Kaiser Permanente Northern California Experience
10.1016/j.thromres.2022.09.022 · 2023 · External reference
Central versus Peripheral CTEPH-Clinical and Hemodynamic Specifications.
10.3390/medicina58111538 · 2022 · External reference
Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: A current understanding
10.1183/09031936.00049312 · 2012 · External reference
Chronic Thromboembolic Pulmonary Hypertension
10.1513/annalsats.201509-621as · 2016 · External reference
Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic.
10.1002/pul2.12038 · 2022 · External reference
The pathophysiology of chronic thromboembolic pulmonary hypertension
10.1183/16000617.0112-2016 · 2017 · External reference
Chronic thromboembolic pulmonary hypertension: The magic of pathophysiology
10.21037/acs-2021-pte-10 · 2022 · External reference
Microvascular disease in chronic thromboembolic pulmonary hypertension: A role for pulmonary veins and systemic vasculature
10.1183/09031936.00169113 · 2014 · External reference
Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension
10.1183/13993003.01787-2018 · 2019 · External reference
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur.
10.1093/eurheartj/ehv317 · 2016 · External reference
Chronic thromboembolic pulmonary hypertension
10.1183/13993003.01915-2018 · 2019 · External reference
The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression.
10.3390/cells10040737 · 2021 · External reference
Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation.
10.3390/cells8020194 · 2019 · External reference
Research progress on the pathogenesis of CTEPH
10.1007/s10741-019-09802-4 · 2019 · External reference
Update on chronic thromboembolic pulmonary hypertension
10.1016/j.tcm.2016.05.010 · 2017 · External reference
Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension.
10.3390/ijms24043979 · 2023 · External reference
Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry
10.1016/j.jtcvs.2010.11.024 · 2011 · External reference
Comparison of balloon pulmonary angioplasty and pulmonary vasodilator for inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis
10.1038/s41598-020-65697-4 · 2020 · External reference
Improved outcomes in medically and surgically treated patients with chronic thromboembolic pulmonary hypertension
10.1164/rccm.200712-1841oc · 2008 · External reference
Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014
10.1080/14017431.2016.1185532 · 2016 · External reference
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
10.1183/13993003.00889-2017 · 2017 · External reference
The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension
10.1183/13993003.00589-2018 · 2018 · External reference
Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling.
10.1177/10760296211013107 · 2021 · External reference
Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8
10.1016/j.cyto.2018.01.007 · 2018 · External reference
Association Between Inflammatory Mediators and Pulmonary Blood Flow in a Rabbit Model of Acute Pulmonary Embolism Combined With Shock.
10.3389/fphys.2020.01051 · 2020 · External reference
IL-1β Blockade Attenuates Thrombosis in a Neutrophil Extracellular Trap-Dependent Breast Cancer Model.
10.3389/fimmu.2019.02088 · 2019 · External reference
Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia
10.1073/pnas.1620458114 · 2017 · External reference
Ectonucleotidase tri (di) phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin 1β-driven venous thrombosis
10.1172/jci124804 · 2019 · External reference
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.
10.1016/j.ebiom.2022.104299 · 2022 · External reference
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
10.1586/1744666x.2014.894886 · 2014 · External reference
The proinflammatory cy-tokine response to coagulation and endotoxin in whole blood
10.1182/blood.v87.12.5051.bloodjournal87125051 · 1996 · External reference
Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8
10.1016/j.cyto.2018.01.007 · 2018 · External reference
Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study
10.1111/j.1538-7836.2004.00689.x · 2004 · External reference
Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease
10.1002/ibd.20759 · 2009 · External reference
TNF-α (Tumor Necrosis Factor-α).
10.1161/atvbaha.118.311660 · 2018 · External reference
Chemokines and disease.
10.1038/84209 · 2001 · External reference
Lymphocyte traffic control by chemokines
10.1038/84219 · 2001 · External reference
The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse.
10.1371/journal.pone.0147958 · 2016 · External reference
Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension
10.1038/s41598-021-98320-1 · 2021 · External reference
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
10.1183/09059180.00007309 · 2010 · External reference
Defective angiogenesis delays thrombus resolution: A potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension
10.1161/atvbaha.113.302991 · 2014 · External reference
Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension
10.1183/09031936.00009914 · 2015 · External reference
Pulmonary vascular endothelium: The orchestra conductor in respiratory diseases: Highlights from basic research to therapy
2018 · External reference
Abnormal pulmonary endothelial cells may underlie the enigmatic pathogenesis of chronic thromboembolic pulmonary hypertension. J. heart Lung Transplant
10.1016/j.healun.2016.08.012 · 2017 · External reference
Inflammatory cytokines regulate endothelial cell survival and tissue repair functions via NF-kappaB signaling
External reference
Nuclear factor kappaB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats
10.1165/rcmb.2013-0355oc · 2014 · External reference
The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression.
10.3390/cells10040737 · 2021 · External reference
The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension
10.1007/s11239-015-1323-2 · 2016 · External reference
Cytokine response to pulmonary thromboendarterectomy
10.1378/chest.126.1.135 · 2004 · External reference
